Interventional, Randomised, Double-blind, Placebo-controlled, Sequential Group, Multiple Dose Study Investigating the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of Lu AF35700 in Patients With Schizophrenia

Trial Profile

Interventional, Randomised, Double-blind, Placebo-controlled, Sequential Group, Multiple Dose Study Investigating the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of Lu AF35700 in Patients With Schizophrenia

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Mar 2015

At a glance

  • Drugs LU AF-35700 (Primary)
  • Indications Schizophrenia
  • Focus Adverse reactions
  • Sponsors Lundbeck A/S
  • Most Recent Events

    • 05 Mar 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 01 Aug 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top